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Background: Several reports indicate a commonly deleted chromosomal region independent from, and distal to
the TP53 locus in a variety of human tumors. In a previous study, we reported a similar finding in a rat tumor model
for endometrial carcinoma (EC) and through developing a deletion map, narrowed the candidate region to 700 kb,
harboring 19 genes. In the present work real-time qPCR analysis, Western blot, semi-quantitative qPCR, sequencing,
promoter methylation analysis, and epigenetic gene expression restoration analyses (5-aza-2´-deoxycytidine and/or
trichostatin A treatments) were used to analyze the 19 genes located within the candidate region in a panel of
experimental tumors compared to control samples.
Results: Real-time qPCR analysis suggested Hic1 (hypermethylated in cancer 1), Inpp5k (inositol polyphosphate-5-
phosphatase K; a.k.a. Skip, skeletal muscle and kidney enriched inositol phosphatase) and Myo1c (myosin 1c) as the
best targets for the observed deletions. No mutation in coding sequences of these genes was detected, hence the
observed low expression levels suggest a haploinsufficient mode of function for these potential tumor suppressor
genes. Both Inpp5k and Myo1c were down regulated at mRNA and/or protein levels, which could be rescued in
gene expression restoration assays. This could not be shown for Hic1.
Conclusion: Innp5k and Myo1c were identified as the best targets for the deletions in the region. INPP5K and
MYO1C are located adjacent to each other within the reported independent region of tumor suppressor activity
located at chromosome arm 17p distal to TP53 in human tumors. There is no earlier report on the potential tumor
suppressor activity of INPP5K and MYO1C, however, overlapping roles in phosphoinositide (PI) 3-kinase/Akt signaling,
known to be vital for the cell growth and survival, are reported for both. Moreover, there are reports on tumor suppressor
activity of other members of the gene families that INPP5K and MYO1C belong to. Functional significance of these two
candidate tumor suppressor genes in cancerogenesis pathways remains to be investigated.
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Allelic loss at 17p is one of the most frequently reported
chromosomal alterations in a variety of human malig-
nancies [1–4]. There are quite a few tumor suppressor
loci reported in this region among which TP53 on
17p13.1 is the most prominent one reported to be
altered in over 40 % of all tumors [5]. However, several
studies clearly provided evidence for presence of an
independent, commonly deleted region or regions at
17p13.3, suggesting the existence of an additional tumor
suppressor gene(s) distal to the TP53 locus [6–9]. Des-
pite many efforts, no definite candidate(s) has yet been
identified.
We have previously reported a similar observation of
an independent tumor suppressor locus distal to Tp53
in an experimental model for endometrial carcinoma
(EC) [10]. Cytogenetic and molecular analysis of ECs de-
veloped in a rat model for this malignancy revealed fre-
quent allelic losses/deletions in the proximal to middle
part of rat chromosome 10 (RNO10) [11–13]. Through
deriving onco-tree models based on allelic imbalance
(AI) data, we determined the likely order of allelic loss
events along RNO10 as well as their relationship to each
other [14]. In the analysis one of the small regions of
recurrent allelic loss located at RNO10q24-q25 was
placed closest to the root of the onco-tree models, sug-
gesting this region to harbor early and important genetic
alterations. The classical tumor suppressor gene Tp53 is
located close to this chromosomal segment and thus was
selected as the candidate. Subsequent analysis, however,
revealed that Tp53 was not the only target [10], and in
fact, the observed pattern for AI, chromosomal breaks
and deletions suggested that major selection was
directed against a region located close to, but distal of
Tp53. This independent, commonly deleted chromo-
somal segment at RNO10q24-q25 is homologous to
the frequently reported loci of tumor suppressor activ-
ity on 17p13.3 in several human malignancies [6–9].
Using the experimental tumor model, we developed a
detailed deletion map and narrowed down the size of
the region to a chromosomal segment of about 700 kb
[10]. There are 19 genes located in this segment,
including several putative tumor suppressor genes,
notably Hic1 (hypermethyalted in cancer 1), Ovca1
(ovarian cancer-associated gene 1), and Ovca2 (ovarian
cancer-associated gene 2) [9]. In the present work, we
subjected the 19 genes located in this candidate region
to expression analysis in a panel of rat EC and non-
malignant endometrium samples. Statistical analysis of
qPCR results combined with subsequent gene muta-
tion screening along with epigenetic and protein ex-
pression analyses suggested Inpp5k and Myo1c as the
most prominent target tumor suppressor candidates in
this region.Results
Real-time quantification PCR
To determine potential target genes for the observed
frequent AI/deletions distal to the Tp53 gene [10], we
determined the expression profile of all the 19 genes lo-
cated in this region in a panel of 28 rat primary tumor
and seven NME (non-malignant endometrium) cell cul-
tures. Nine of the genes displayed significant decreased
expression in EC compared to the NME samples (nom-
inal P-value < 0.05, Fig. 1, Table 1). The question was
then whether the observed reduced expression of these
nine genes was due to the physical deletion of the
genetic material or other regulatory mechanisms. To
address this, we used earlier CGH, AI, and FISH data
[12, 13, 15, 16] and divided the 28 tumors analyzed in
the gene expression assays into two groups: ECs with
deletion/AI and those without deletion/AI spanning the
700 kb candidate chromosomal segment. We subse-
quently used this new grouping of tumors and re-
analyzed the real-time RT-PCR results to determine
whether there existed a correlation between physical
deletion and the observed lowered expression of the
nine genes among the tumor groups. Lowered expres-
sion of five genes (Hic1, Rpa1, Inpp5k, Myo1c and Crk)
was found to lack correlation with the physical deletion in
the region (Table 1), suggesting the involvement of other
regulatory mechanisms in silencing of these genes. Fold
change in expression of Rpa1 was minimal and Crk is
mostly known as an oncogene. The remainder three genes
were thus selected as candidates for further analysis.
Western blot analysis of Hic1, Inpp5k and Myo1c
expressions
Based on qPCR results, five rat ECs with differential
expressions of Hic1, Inpp5k and Myo1c and from differ-
ent genetic backgrounds as well as three NME samples,
as control (Additional file 1: Table S1), were selected for
Western blot analysis to validate the qPCR data. The
analysis revealed no decrease in the expression of Hic1
protein in EC compared to the NME samples (Fig. 3a
and 3b). The Myo1c protein expression levels correlated
well with the observed qPCR fold changes and down
regulation of Myo1c protein expression was detected in
four out of five ECs compared to the NME samples
(Fig. 3a and 3b). Our attempts for expression analysis of
Inpp5k protein in this sample set failed, most likely due
to the problem with specificity of the purchased anti-
body for rat samples that is produced against the human
INPP5K protein.
DNA sequencing and mutation analysis of Hic1, Inpp5k
and Myo1c
To screen Hic1, Inpp5k and Myo1c genes for potential
inactivating mutations, the entire coding regions of
Table 1 Changes in relative expression of 19 genes within tumor suppressor region located at 62.3 – 63.0 Mb (RNO10q24)
distal to Tp53
Transcript Position
(Mb)
Group EC vs NME Group EC with vs EC without loss at RNO10q24
P-value <0.05 Fold change P-value <0.05
Est1a 62.23 0.002 x −2.3 0.03 x
Hic1 62.47 0.0004 x −4.9 0.2
Ovca2 62.48 0.760
Dph1 62.49 0.973
Rtn4rl1 62.50 0.008 x −4.5 0.02 x
Rpa1 62.61 0.003 x −1.9 1.1
Smyd4 62.66 0.918
Serpinf1 62.71 0.293
Serpinf2 62.75 0.324
Wdr81 62.76 0.00.5 x −1.7 0.01 x
Tlcd2 62.79 0.218
Prf8 62.81 0.054
Rilp 62.83 0.108
Scarf1 62.84 0.811
Slc43a2 62.85 0.247
Pitpn 62.91 0.0003 x −2.2 0.0004 x
Inpp5k 62.95 0.0003 x −6.8 0.2
Myo1c 62.99 0.000003 x −4.8 0.1
Crk 63.02 0.00001 x −3.2 0.4
Nine genes displayed significant decreased expression (nominal p-value < 0.05) in EC compared to the NME samples. Tumors were then divided into two groups
of with and without deletion/AI at RNO10q24 and the gene expression data for the nine down regulated genes were reanalyzed. Down regulation of five genes
(marked in bold) was not correlated with physical deletion at RNO10q24
Fold changes and P-values of the different transcripts. The negative values of fold change represent a decreased expression. FC shown only for genes displaying
P-values <0.05 between NME vs EC
Equal variances assumed. t-test for equality of means
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of Myo1c were sequenced using genomic DNA from
tumor cell cultures and the parental rat strains (BDII,
BN and SPRD) as template (Additional file 1: Table S1).
No mutation in Hic1, Inpp5k or Myo1c was found.
Sequence analysis of Hic1 and Myo1c revealed 10
strain specific variations within these genes: five in Hic1
(two in noncoding and three in coding sequences,
Additional file 2: Table S5) and five in Myo1c (all in non-
coding sequences, Additional file 2: Table S5). It is im-
portant to note that one of the identified SNPs in the
coding sequence of Hic1 gene (at nt 62474413) results in
a non-conservative amino acid substitution in BDII
strain, from nonpolar alanine (Ala177) to polar threo-
nine (Thr177, Additional file 2: Table S5).
Methylation analysis of Hic1, Inpp5k and Myo1c
To investigate the potential involvement of epigenetic
inactivation of the three candidate genes in tumors with-
out physical deletion, a panel of tumors with or without
deletion in the region, and with differential expressions
of the Hic1, Inpp5k and Myo1c, were subjected to DNAmethylation analysis. The overall methylation profile of
CpG islands in Hic1, Inpp5k and Myo1c promoter re-
gions was characterized using the bisulfite genomic se-
quencing method in a panel of 18 samples, including 14
ECs (Additional file 1: Table S1), three parental strains
(BDII, BN and SPRD) and a positive control sample
(methylase treated BDII). This analysis was complemen-
ted with the MSP method for parts of Hic1 promoter
region for which bisulfite sequencing was not successful
(data not shown). Using the CpG Island Searcher pro-
gram (http://www.uscnorris.com/cpgislands2/cpg.aspx),
the promoter region of the Hic1 gene was found at
position −1352 to −476 (877 bp, including 47 CpG sites).
Bisulfite genomic sequencing (for 26 CpGs) combined
with MSP analysis (for the remainder 21 CpGs) revealed
partial promoter methylation in 9 out of 14 (64 %) of the
tumors (Fig. 3c). The Inpp5k promoter was located at
position −517 to +53 (570 bp, containing 53 CpG sites).
The location of the promoter region of the Myo1c gene
was found at position −2000 to −1111 (890 bp, including
55 CpG sites). No methylation was detected in the
Inpp5k and Myo1c promoters in the tumors analyzed,
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detected in the Hic1. The detected Hic1 promoter
methylation was not correlating with the Hic1 expres-
sion at RNA and/or protein levels Fig. 3c.
Restoration of gene expression after 5-Aza-dC and/or TSA
treatments
To investigate whether other epigenetic mechanisms
might be involved in the reduction of expression of the
three candidate genes we subjected a selected panel of
cells to restoration of gene expression treatments. We
selected four EC cell lines with reduced Myo1c, Hic1,
and/or Inpp5k expression (NUT12 and NUT50 with,
and NUT51 and NUT98 without deletion/AI in the can-
didate region RNO10q24-q25) as well as REF (rat em-
bryonic fibroblast) cells for the analysis. Gene expression
analysis at both RNA and protein levels, as expected, re-
vealed no restoration of Hic1, Innp5k and Myo1c ex-
pressions after 5-Aza-dC and/or TSA treatments in the
control cell REF (Fig. 4). The analysis also showed no or
a marginal restoration (only after AZA treatment in
NUT51) of gene expression for Hic1 after either or both
treatments in the tumor samples tested Fig. 4a, d and e).
RT-PCR analysis revealed a strong restoration of Inpp5k
expression following 5-Aza-dC and/or TSA treatments
in three of the tumors analyzed (NUT50, NUT51 and
NUT98, Fig. 4b). For the Myo1c gene, a marginal restor-
ation of gene expression after the treatments was de-
tected in RT-PCR analysis, in particular for NUT50
(Fig. 4c). Analysis of Myo1c protein, however, was more
conclusive and clearly showed that expression of Myo1c
protein was partially restored after the treatments, espe-
cially in NUT12 (with physical deletion/AI in the region)
and NUT98 (without physical deletion/AI in the region)
as well as in NUT50 (with deletion/AI in the region)
after the combined treatments (Fig. 4e).
Discussion
In the present work and by using a set of well-
characterized experimental EC tumor samples, and
through a candidate gene approach, we characterized
the frequently reported independent region of tumor
suppressor activity in human tumors located telomeric
to TP53. We subjected all 19 genes located in this
chromosomal segment to gene expression analysis in a
panel of 28 rat EC and seven control non-malignant
endometrium (NME) samples. Nine genes showed
significant reduced expression in EC compared to
NME samples (Fig. 1, Table 1). Interestingly, two of
the known tumor suppressor genes located in this
region, Ovca1 (ovarian cancer-associated gene 1) and
Ovca2, were not among these.
The question was then whether the observed reduced
expression of these nine genes was due to the physicaldeletion of the genetic material or other regulatory
mechanisms. To address this, we used earlier CGH, AI,
and FISH data [12, 13, 15, 16] and divided the 28 tumors
analyzed in the gene expression assays into two groups:
ECs with deletion/AI and those without deletion/AI
spanning the 700 kb candidate chromosomal segment.
We subsequently used this new grouping of tumors and
re-analyzed the real-time RT-PCR results to determine
whether there existed a correlation between physical
deletion and the observed lowered expression of the
nine genes between the tumor groups (Fig. 2, Table 1).
Our interest was to identify gene(s) showing no such
correlation, indicating that the observed reduction in
expression of these gene(s) was not only due to the
physical deletion of the genetic material. The results
revealed that lowered expression levels of five genes,
Hic1, Rpa1, Inpp5k, Myo1c and Crk were independent of
the observed physical deletions (Fig. 2, Table 1). Among
these, Hic1, Inpp5k and Myo1c showed strong and highly
significant down regulation in EC compared to the
control samples (Table 1) and thus were selected as the
best candidates. Rpa1 and Crk were not appealing as
candidates: Rpa1 showed only a rather moderate down
regulation in gene expression analysis (Table 1) and Crk
(v-crk sarcoma virus CT10 oncogene homolog, avian) is
mainly recognized as an oncogene in cancer studies
[17–19].
In qPCR experiments, we found that Hic1, Innp5k and
Myo1c were always expressed in the tumors, although at
very low levels. According to Knudson’s theory of inacti-
vation of tumor suppressor genes [20], if Hic1, Inpp5k
and Myo1c are to behave as classical tumor suppressor
genes, it is expected that both alleles of the genes be
inactivated in the tumor material. We, therefore, hypoth-
esized that the remaining allele of these genes might
have become inactivated through mutation/s. However,
in gene sequencing experiments, no mutation was found
in coding sequences of these three genes, suggesting a
potential haploinsufficient mode of function for these
candidate tumor suppressor genes. In gene sequencings
we identified ten SNPs in intronic, noncoding and/or
coding sequences of the Hic1 and Myo1c genes
(Additional file 2: Table S5). Identification of these SNPs
offered the possibility to confirm our earlier AI/deletion
data [11, 13] and also to make a detailed deletion map with
information on the homozygote/hemizygote pattern of the
observed deletions spanning the candidate region in the
tumors.
Our interest was then to determine whether gene
products of these three candidate genes were down reg-
ulated in the tumors. To this end, we examined expres-
sion of Hic1, Innp5k and Myo1c proteins in a selected
panel of five ECs compared to three NME samples using
Western blot. The result for Myo1c showed a good
Fig. 1 Results of Real-time RT-PCR analysis revealed significant reduced expression of nine genes (nominal P value < 0.05) in a panel of 28 rat
endometrial carcinomas (EC) compared to seven non-malignant (NME) samples. NME, non-malignant endometrium; EC, rat EC tumors; Fold
(fold changes): magnitude of difference in gene expression between the two groups of samples (EC vs NME); P, nominal P value
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expression level in the tumor samples, indicating that
Myo1c protein was in fact down regulated in the ma-
jority of EC tumors tested compared to the control
samples (Fig. 3a and b). However, such a correlation
was not detected for Hic1 as it was shown that expres-
sion of Hic1 protein was not down regulated in the
tumors, even in those showing a rather strong Hic1
down regulation at their mRNA level (NUT12, NUT51
and NUT98; Fig. 3a and b). No result was obtained for
the Inpp5k protein, most likely due to the lack ofspecificity of the available human antibody for the rat
samples.
There were a number of tumors that did not harbor
AI/deletion in the candidate region, but nevertheless
displayed a significant down-regulation of Hic1, Inpp5k
and/or Myo1c (Table 1). The question was then whether
other regulatory machineries, namely epigenetic regula-
tion, were involved. To address this, we screened
promoter regions of Hic1, Inpp5k and Myo1c for methy-
lation at CpG islands. No methylation was detected in
the Inpp5k and Myo1c promoter regions in any of the
Fig. 2 Comparative analysis of relative expression of nine genes between groups of EC tumors with and without chromosomal deletion (14 tumors in
each group) in the candidate region. Five genes (Hic1, Rpa1, Inpp5k, Myo1c and Crk) were almost equally down regulated in both groups of tumors
(nominal P value > 0.05), suggesting reduction in expression of these genes was not correlated with physical deletion at the candidate chromosomal
region and thus regulated by other mechanisms
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detected in Hic1 promoter in 64 % of tumors tested
(Fig. 3c). No correlation, however, between the observed
methylation status of Hic1 promoter and the level of
Hic1 transcript was detected in tumor samples (Fig. 3c).
It is quite common that genes with critical functions
are under restricting regulation by several promoters.
Moreover, histone deacethyaltion is an alternative epi-
genetic regulation mechanism that may also result in the
gene silencing. To examine whether other potentialpromoter(s) might have been involved in the expression
regulation of Hic1, Inpp5k and Myo1c as well as to study
the potential involvement of histone deacethylation in
expression regulation of these genes, we treated cell lines
with demethylating agent 5-Aza-dC and/or deacetylating
inhibitor TSA. Surprisingly, Hic1 expression was not
specifically restored after the treatments in the samples,
especially not in those that showed partial methylation
in the Hic1 promoter region (NUT12 and NUT51,
Figs. 3c, 4a, d and e). This result suggested that the
Hic1
Myo1c
0 12.5 37.5 62.5 100%87.5
N
U
T4
N
U
T5
2
N
U
T5
1
N
U
T5
0
N
U
T1
4
N
U
T1
2
N
U
T6
R
U
T2
N
U
T1
28
N
U
T8
2
N
U
T7
6
R
U
T3
0
R
U
T6
R
U
T1
3
BD
II+
SP
R
D
BNBD
II
-0.6 -2.5 -3.3-2.1-2.1-2.7-4.3 -2.2-3.3-2.6-3.5-6.7-2.50.1qPCR FC
Methylation 
percentage
NU
T1
2 
NU
T4
7 
NU
T5
1 
NU
T7
6 
NU
T9
8 
NM
E1
8 
NM
E1
22
NM
E1
23
Myo1c
Hic1
Gapdh
c
a
b
qPCR FC -1
.3 0.
6
-1
.4 1.
2
1.
9
2.
3
2.
5
-2
.1
- 4
.3
- 0
.9
-2
.1 0.
1
0.
4
0.
7
0.
5
-2
.5
Fig. 3 a and b Analysis of Myo1c and Hic1 protein expression in five EC and three NME samples. The results shown are representative of three
independent experiments. Myo1c protein displayed down regulated in four out of five ECs tested, whereas Hic1 protein was not down regulated
in the EC samples, even in those that in qPCR experiment showed a strong lowered expression of Myo1c transcript. The analysis additionally
showed a very good correlation between expression of Myo1c at RNA and protein levels in the tumors tested, whereas such correlation was not detected
for Hic1. EC: enodemetrail carcinoma; NME: non-malignant endometrium. c Methylation status of CpG islands in promoter regions of Hic1 (26 CpG sites)
and Myo1c in a panel of 14 ECs, three parental strains (BDII, BN and SPRD) and one positive control (BDII +) samples. Methylation frequencies are color
coded (black, ranges of gray and white) in five white/gray/black grades corresponding to percentages of CpG sites that were found methylated in each
sample. For comparison, qPCR results for the Hic1 gene is presented as fold changes (FC) for each tumor, where negative and positive fold change values
represent reduced and increased expressions, respectively. As shown, a correlation between methylation score at the Hic1 promoter and expression of this
gene in tumors is lacking. No methylation was identified in the promoter region of Myo1c
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region in EC tumors, rather than being an epigenetic si-
lencing mechanism, is likely to be a general structural
feature for this gene. In agreement with this, dense
hypermethylation of one of the HIC1 alleles has earlier
been reported in a number of normal human tissues,
including kidney [21], and histologically normal and
benign hyperplastic prostate tissues [22].Restoration of gene expression was detected for
Myo1c and Inpp5k genes in the tumor samples at RNA
and/or protein levels (Fig. 4b-e). Notably, the observed
gene expression restoration for Myo1c protein was
irrespective of AI/deletion in the candidate region, as
NUT12 with AI/deletion and NUT98 without AI/dele-
tion showed strong restoration of Myo1c expression
after either or both treatments (Fig. 4e). These data
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Fig. 4 Expression patterns of Hic1, Inpp5k and Myo1c after treatments with 5-Aza-dC and/or TSA in four tumors (NUT12 & NUT50 with and
NUT51 & NUT98 without deletion in the candidate region) and one control (rat embryonic fibroblast, REF) samples. The results shown are
representative of two independent experiments. a Hic1 mRNA expression, b Inpp5k mRNA expression, c Myo1c mRNA expression, d protein
expression of Hic1 and Myo1c, and e quantification of Western blot analysis for Hic1 and Myo1c expressions. As shown, expression of Hic1 was
not specifically restored in these assays (only after AZA treatment in one sample, NUT51), whereas expressions of Myo1c (at both mRNA and protein levels)
and Inpp5k (at mRNA level) were restored after either or both of these treatments. Interestingly, restoration of Myo1c gene expression was observed in
both tumors with (NUT12) and without (NUT98) AI/deletion in the region
Hedberg Oldfors et al. BMC Genetics  (2015) 16:80 Page 9 of 13suggest that epigenetic gene silencing might have an im-
portant role in inactivation of Myo1c and Inpp5k tumor
suppressor candidates.
To summarize, qPCR analysis of 19 genes located
within the commonly deleted region distal to Tp53 in
experimental ECs, suggested Hic1, Inpp5k and Myo1c as
the best candidate tumor suppressor genes in this re-
gion. No mutation was detected in the coding sequences
of the retained alleles, suggesting a potential haploinsuf-
ficient mode of function for these candidate tumor sup-
pressor genes. Hic1, Inpp5k, and Myo1c showed reduced
expression in tumor samples irrespective of the presence
or absence of physical deletion in the candidate region,
suggesting the potential involvement of alternative gene
silencing regulatory mechanism(s). We found a rather
normal expression of Hic1 protein in the tumors, even
in those that showed down regulation of Hic1 at the
mRNA levels, indicating lack of correlation between ex-
pression of Hic1 at mRNA and protein levels. Promoter
methylation analysis revealed partial methylation of Hic1
promoter in a number of tumors. Nevertheless, there
was again no correlation between the presence or ab-
sence of Hic1 promoter methylations and gene expres-
sion levels in the tumors. Moreover, Hic1 expression
could not specifically be restored after treatments with
demethylating and histone deacetylase inhibitor agents.
In contrast, while promoter methylation was not de-
tected in Inpp5k and Myo1c promoters, down regulation
of Inpp5k and Myo1c were detected in EC tumors, and
this could be rescued after the 5-Aza-dC and TSA
treatments, even in tumors without AI/deletion in the
candidate tumor suppressor region. Taken together, re-
sults from the present work exclude Hic1 as a fitting
candidate and provide evidence for Inpp5k and Myo1c as
two attractive candidates for the observed independent
tumor suppressor activity at the neighborhood of Tp53.
INPP5K (inositol polyphosphate-5-phosphatase K, also
known as SKIP, skeletal muscle and kidney enriced inosi-
tol phosphatase) is a member of the inositol polyphos-
phate 5-phosphatases family [23] with a poorly
characterized function in vivo. The inositol polyphos-
phate 5-phosphatases family is known as negative regu-
lators of PI 3-kinase signaling [24]. Analysis of the role
of INPP5K in insulin-stimulated cells indicated that en-
dogenous INPP5K might be one of the key regulators ofinsulin signaling in skeletal muscle and adipocytes for
glucose homeostasis [25]. INPP5K was identified as a 5'-
inositol phosphatase that hydrolyzes phosphatidylinositol
3,4,5-triphosphate (PI-3,4,5-P3) and phosphatidylinositol
4,5-bisphosphate (PI-4,5-P2) to negatively regulate intra-
cellular phosphatidylinositol 3-kinase signaling. It is thus
suggested that INPP5K exerts its functions through
direct binding to PIP3 or forming a complex with
molecules located downstream of PI 3-kinase. Activated
PI 3-kinase generates PIP3 that in turn activates the
downstream target AKT, which then positively regulates
a range of cellular functions, including actin rearrange-
ment, protein synthesis, cell metabolism, cell cycle (G1-S
transition) and cell survival [24]. So far, there is no report
on potential involvement of INPP5K in cancer progression.
However, another member of the phosphoinositide phos-
phatase family, PTEN, has already been identified as a
haploinsufficient tumor suppressor gene [26] and its
inactivation has been implicated in a variety of human
cancers, including endometrial carcinoma. Therefore, it
is tempting to speculate that INPP5K might likewise be
potentially involved in carcinogenesis.
The gene adjacent to Inpp5k, and the second candi-
date tumor suppressor gene identified in the present
work, is the molecular motor myosin 1c (Myo1c). Myo1c
exerts overlapping functions in phosphoinositide (PI) 3-
kinase/AKT (PI3K/AKT) signaling as those of Inpp5k.
Myosin 1C is a widely expressed vertebrate unconven-
tional myosin-I isoform that concentrates in perinuclear
regions, on ruffling cell membranes, and within stereo-
cilia of hair cells. Increasing evidence points to the role
of myosin 1c in many signaling cascades, from the
integrin-dependent signaling involved in cell migration
to the signaling events underlying insulin resistance
(reviewed in [27]). Myo1c is a lipid raft-associated motor
protein that is specifically involved in the recycling of
lipid raft membrane and proteins that regulate plasma
membrane plasticity, cell motility and pathogen entry
[28, 29]. MYO1C binds tightly and specifically to PIP2
[30], an important second messenger involved in a var-
iety of crucial cellular functions, including regulation of
the actin cytoskeleton and signal transduction in insulin
and AKT signaling pathways. This protein is additionally
involved in glucose uptake in muscle and adipocytes
through controlling of movement of intracellular GLUT4–
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been shown that insulin-dependent phosphorylation of
Myo1c is required for GLUT4 translocation and transport
of glucose through phosphoinositide (PI) 3-kinase/AKT
pathway [32, 33]. There is no earlier report on potential
tumor suppressor activity of this gene, but several other
members of the myosin-I gene family have been reported
as cancer-related genes, including tumor suppressor gene
MYO18B in lung, ovarian and colorectal cancer [34] and
involvement of MYO1F in chromosomal translocation and
gene fusion in infant acute monocytic leukemia [35].Conclusions
In conclusion, our data suggested Inpp5k and Myo1c as
potential candidates located adjacent to each other
within the reported independent tumor suppressor loci
distal to Tp53. There is no earlier report on their poten-
tial involvement in carcinogenesis, but earlier studies
have clearly suggested a regulatory role for these genes
in PI3K/Akt pathway, which is known to be vital to the
growth and survival of cancer cells [36]. Moreover, other
members of gene families that INPP5K and MYO1C be-
long to are suggested to function as tumor suppressor
genes in a variety of cancer types [26, 34]. Details of
potential functional contributions of these two genes
to cancerogenesis remain to be further investigated.Methods
Animal crosses and experimental tumor material
All animal experiments were approved by the local eth-
ical committee (Institute of Laboratory Animal Science
and Central Animal Facility, Hannover Medical School).
Animals of the inbred BDII rat strain are genetically pre-
disposed to spontaneous EC, with an incidence of more
than 90 % in virgin females before the age of 24 months
[37, 38]. EC tumors developed in F1, F2 and backcross
(N1) progeny of crosses between BDII females and males
from two EC non-susceptible strains, BN/Han and
SPRD-Cu3/Han [39, 40], were included in the present
study (Additional file 1: Table S1). In some cases no
malignant cells were detected in the removed cell
mass from animals when pathologically characterized.
Chromosomal analysis of these samples revealed only
minor numerical chromosomal changes (unpublished
data). In this study these tissues represent normal or
pre-malignant endometrium and thus are referred to as
non-malignant endometrium (NME, Additional file 1:
Table S1). At necropsy, tumor specimens were collected
from animals for DNA extraction using a standard
phenol-based method in the Genepure™ 341 Nucleic
Acid Purification System (PE Applied Biosystems) [12].
Small pieces of fresh tumor as well as NME tissues were
used to set up primary cell cultures. From the cellcultures, DNA and total RNA were extracted using the
GenElute kit (Mammalian Total RNA Kit, Sigma).
Real-time quantitative PCR
Expression of 19 genes (Table 2) was analyzed in a panel
of 28 EC and seven NME samples using Real-time quan-
titative PCR as described previously [41]. Quantification
and normalization of the results was performed by the
standard-curve method. Briefly, a standard curve was
prepared in each PCR assay for all genes using serial di-
lutions (1:1, 1:3, 1:9, 1:18, 1:36, and 1:72) of one of the
tumor samples (RUT30) and/or a commercially available
rat RNA mix (Stratagene, La Jolla, CA, USA). The mean
CT-value for triplicates was calculated, CT values of the
serial dilutions were used to interpolate standard curves
for each gene and data therein was used to determine
concentration or copy number of each gene in every test
sample. To normalize the results, three housekeeping
genes (Gapdh, β-actin and Rps9) were included in the
analysis, among which Rps9 (ribosomal protein S9)
showed the lowest variations in ΔCT levels regardless of
the cell type [41] and thus was selected and used as the
internal reference for normalization of expression of all
19 genes in the samples. Logarithmic expression levels
were then compared with Welch's t-test for adjusted
expression levels based on standard curves as well as
expression of Rps9 in EC tumors compared to NME
samples.
Western blot
A panel of five EC and three NME samples was analyzed
by western blot to examine levels of Hic1, Inpp5k and
Myo1c protein expression using 1:500 rabbit anti-Hic1
(H8539, Sigma Aldrich), 1:1000 rabbit anti-Inpp5k (S8948,
Sigma Aldrich), 1:600 rabbit anti-Myo1c (HPA001768,
Sigma Aldrich), and 1:500 dilution anti-Gapdh (sc-825778,
Santa Cruz, Biotechnology) according to the standard
protocol (Additional file 1: Table S1, Fig. 3a and b).
DNA sequencing of Hic1, Inpp5k and Myo1c
A panel of 32 EC tumors was selected for mutation
sequencing of Hic1 and Myo1c (Additional file 1: Table
S1). The Inpp5k gene was sequenced in 18 tumors.
Primer pairs were designed using the Primer3 program
and synthesized by a commercial supplier (SIGMA-
Genosystem, Cambridge, UK). PCR primers set corre-
sponding to the coding sequences of Hic1, Inpp5k and
Myo1c genes were amplified and screened for muta-
tions (Additional file 3: Table S2). For the Myo1c gene
the promoter region was also sequenced.
PCR amplification products were purified using GFX™
PCR DNA and gel Band Purification Kit (Amersham
Pharmcia Biotech, Piscataway, NJ). Using ABI PRISM®
BigDye® Terminator v1.1 or 3.1 Cycle Sequencing Kit
Table 2 Genes located within tumor suppressor region between 62.3-63.0 Mb on RNO10 at band 10q24 which is homologous to
human chromosome band 17p13.3
Start (Mb) Gene Description Accession no. Assay ID
62.23 Est1a Telomerase-binding protein EST1A (Ever shorter telomeres 1A) NM_001105808 Rn01466713_m1
62.47 Hic1 Hypermethylated in cancer 1 NM_001107021 CM-Hic1
62.48 Ovca2 Candidate tumor suppressor OVCA2 NM_001109036 CM-Ovca2
62.49 Ovca1 Candidate tumor suppressor OVCA1, Dph2l1 NM_001105809 CM-Ovca1
62.50 Rtn4rl1 Reticulon 4 receptor-like 1 NM_181377 Rn01648154_m1
62.61 Rpa1 Replication protein A1 NM_001047843 Rn01460703_g1
62.66 Smyd4 SET and MYND domain containing 4 NM_001105810 CM-Smyd4
62.71 Serpinf1 Serine (or cysteine) peptidase inhibitor, clade F, member 1 NM_177927 Rn00709999_m1
62.75 Serpinf2 Serine (or cysteine) peptidase inhibitor, clade F, member 2 NM_001011892 Rn01464596_m1
62.76 Wdr81 Wdr81, WD repeat domain 81 NM_001134360 Rn01460094_m1
62.79 Tlcd2 TLC domain containing 2 XM_573142.2 Rn01465130_m1
62.81 Prpf8 Pre-mRNA processing factor 8 XM_001080695 Rn01472027_g1
62.83 Rilp Rab interacting lysosomal protein NM_001105811 Rn01465376_g1
62.84 Scarf1 Scavenger receptor class F, member 1 NM_001107022 CM-Scarf1
62.85 Slc43a2 Solute carrier family 43, member 2 NM_001105812 CM-Slc43a2
62.91 Pitpna Phosphatidylinositol transfer protein, alpha NM_017231 Rn01464411_m1
62.95 Skip Skeletal muscle and kidney enriched inositol phosphatase NM_001013859 Rn01466844_g1
62.99 Myo1c Myosin IC NM_023092 Rn00576538_m1
63.02 Crk V-crk sarcoma virus CT10 oncogene homolog (avian) NM_019302 Rn00467066_m1
1q12 Rps9 Ribosomal protein S9 NM_031108.2 Rn01530912_g1
4q42 Gapdh Glyceraldehyde-3-phosphate dehydrogenase NM_017008.3 Rn99999916_s1
12p11 β-actin Beta-actin NM_031144 Rn00667869_m1
TaqMan assays used in quantitative real-time PCR for the genes in the region as well as three housekeeping genes are presented
CM: Custom made
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subjected to sequencing according to the protocol pro-
vided by the manufacturer. Sequencing products were
separated on a denaturing polyacrylamide gel on a
3130xl Genetic Analyzer (Applied Biosystems) and ana-
lyzed using the software’s Sequencing Analysis v5.2 and
SeqScape v2.5 (Applied Biosystems).
DNA methylation analysis
A panel of 14 tumors was selected for promoter methy-
lation analysis of Hic1, Inpp5k and Myo1c (Additional
file 1: Table S1). One μg DNA from 14 tumors as well as
the three controls (parental strains: BDII, BN and SPRD)
were denatured, treated by sodium bisulfite and purified
using Epitect Bisulfite Kit according to manufacturer
protocol (Qiagen). A positive control sample was pro-
duced through methylase treatment of DNA from BDII.
This sample was then sodium bisulfite treated and
processed at similar conditions as the test samples. We
used web server CpG Island Searcher (URL: http://
www.uscnorris.com/cpgislands2/cpg.aspx) to predict lo-
cation of CpG islands for both genes. Primers suitable
for bisulphite sequencing were designed using the Meth-Primer software (URL: http://urogene.org/methprimer/)
and BiSearch web server (URL: http://bisearch.enzim.hu/)
and synthesized by a commercial supplier (SIGMA-
Genosystem, Cambridge, UK). Promoter regions were
PCR amplified using two different overlapping sets of
primer for Hic1 and three sets of primers for Myo1c
using treated DNA as template (Additional file 4:
Table S3). In some cases it was necessary to perform
semi-nested PCR to produce enough PCR products for
sequencings. The methylation status was then analyzed
using bisulphite sequencing as described earlier [42].
Our attempts to PCR amplify and sequence the middle
part of the Hic1 promoter (−1082 to −781) failed. This
was mainly due to high density of CpGs in the sequence.
We thus analyzed methylation status of this part of the
Hic1 promoter using the MSP (methylation specific
PCR) technique. Primer pair sequences and PCR condi-
tions are available upon request
5-aza-2´-deoxycytidine (5-Aza-dC) and/or trichostatin A
(TSA) treatment
Four EC cell lines (NUT12 and NUT50 with and
NUT51 and NUT98 without deletion/AI at RNO10q24)
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rat embryo fibroblasts (REF), were selected for the
analysis. All cell cultures were treated with the demethy-
lating agent 5-aza-2´-deoxycytidine (5-Aza-dC, Sigma-
Aldrich Co, St Louis, MO, USA) and/or with the histone
deacetylase inhibitor trichostatin A (TSA; Sigma-Aldrich).
Concentrations of the agents for treatments were chosen
based on an earlier study (Karlsson et al., unpublished data).
Each cell line was seeded at low density in four separate
flasks, treated with 5-Aza-dC, TSA, both 5-Aza-dC and
TSA, or no treatment. For 5-Aza-dC treatments, cells were
grown in medium containing 2.5 μM 5-Aza-dC for
96 hours, with medium and drug being refreshed twice
after 48 h and 72 h. For simultaneous 5-Aza-dC and TSA
treatments, the procedure was as 5-Aza-dC treatment, with
the addition of 300 nM TSA to the culture during the last
16 hours. For the TSA treatment as well as the negative
control, medium was refreshed after 48 h and 72 h, with
the exception that for the TSA treatment, 300 nM TSA
was added to the culture during the last 16 hours.
Two independent experiments for all treatments and
tumor samples were performed. After 96 hours, total
RNA was isolated from all samples using RNeasy Pro-
tect Mini kit (Qiagen) according to the manufacturer’s
protocol. Protein extraction was performed according
to standard protocols.Semi quantitative RT-PCR
Reverse–transcription polymerase chain reaction (RT-PCR)
was performed on 1 μg of total RNA using QuantiTect®
Reverse Transcription Kit (Qiagen) according to manufac-
turer’s protocol. Semi quantitative RT-PCR was performed
for Hic1, Inpp5k and Myo1c using β-actin as internal
control in multiplex PCR. Primer pairs were designed
using the Primer3 program and were synthesized by
a commercial supplier (SIGMA-Genosystem, Cambridge,
UK) (Additional file 5: Table S4). PCR amplification was
performed for 26 cycles.Additional files
Additional file 1: Table S1. Panel of cell cultures used in the present
study. Different sets of samples were used for different analysis as: Mut,
mutation sequencing (32 EC); qPCR (28 EC and seven NME), Real-time
PCR; WB, Western blot (five EC and three NME); PM, promoter methylation
(14 EC); AT, 5-Aza-dC/TSA treatments (four EC and one NME).
Additional file 2: Table S5. SNPs identified in the gene sequencing
analysis based on the build RGSC3.4 data.
Additional file 3: Table S2. Primers used for sequencing the genes
Hic1, Myo1c and Inpp5k.
Additional file 4: Table S3. Primers used for bisulphite sequencing of
the promotors of Hic1 and Myo1C. For Hic1 the predicted CpG island was
877 bp and includes 47 CpG sites. For Myo1c the predicted CpG island of
890 bp and includes 55 CpG sites.Additional file 5: Table S4. Primers used for semi quantitative multiplex
RT-PCR for Hic1, Inpp5k and Myo1c amplified in a multiplex PCR with β-actin
as the internal control.
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